Compare KWR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | ZYME |
|---|---|---|
| Founded | 1918 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1994 | 2022 |
| Metric | KWR | ZYME |
|---|---|---|
| Price | $135.46 | $26.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $167.00 | $38.90 |
| AVG Volume (30 Days) | 152.0K | ★ 517.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $1,888,634,000.00 | $105,965,000.00 |
| Revenue This Year | $5.16 | $183.10 |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $124.21 | ★ N/A |
| Revenue Growth | 2.66 | ★ 38.87 |
| 52 Week Low | $99.18 | $10.89 |
| 52 Week High | $183.01 | $29.75 |
| Indicator | KWR | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 49.47 |
| Support Level | $133.86 | $22.28 |
| Resistance Level | $143.53 | $27.35 |
| Average True Range (ATR) | 5.94 | 1.03 |
| MACD | 0.33 | -0.23 |
| Stochastic Oscillator | 53.36 | 11.52 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.